Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: Conversations from the Front Lines of Drug Development
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 15

December 01, 2021 00:40:52
Episode Cover

Episode 15: Dr. Terry Jo Bichell, Founder and Director of COMBINEDBrain

Raising awareness for rare diseases, such as Angelman Syndrome, should not be something parents, patients, and advocates have to do alone. Today's episode of...

Listen

Episode 37

January 24, 2024 00:41:31
Episode Cover

Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche

"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...

Listen

Episode 33

September 20, 2023 00:26:33
Episode Cover

Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals

Listen